Agenus | AGEN - Current Assets


Agenus reported $133.95M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
AbbVie USD 28.54B 722M Sep/2025
Agenus USD 133.95M 120.61M Sep/2025
Amgen USD 29.06B 1.17B Dec/2025
AstraZeneca USD 28.72B 1.22B Dec/2025
Bristol-Myers Squibb USD 35.63B 2.41B Sep/2025
Celldex Therapeutics USD 604.34M 44.06M Sep/2025
CSL USD 11.85B 542M Jun/2025
Dynavax Technologies USD 814.33M 28.62M Sep/2025
Eli Lilly USD 62.07B 12.22B Sep/2025
Gilead Sciences USD 19.89B 1.05B Dec/2025
GlaxoSmithKline GBP 17.51B 332M Dec/2025
Glaxosmithkline GBP 23.98B 6.31B Sep/2025
Incyte USD 5.02B 746.01M Dec/2025
Intrexon USD 23.72M 45.04M Jun/2024
J&J USD 55.62B 1.01B Dec/2025
Jiangsu Hengrui CNY 51.4B 4.64B Sep/2025
Karyopharm Therapeutics USD 89.75M 8.12M Sep/2025
MacroGenics USD 232.09M 27.15M Sep/2025
Merck EUR 12.88B 680M Sep/2025
Merck USD 47.56B 10.49B Sep/2025
Novartis USD 28.2B 2.26B Sep/2025
Novavax USD 974.59M 55.08M Sep/2025
Pfizer USD 46.92B 3.22B Sep/2025
Regeneron Pharmaceuticals USD 18.02B 41.2M Dec/2025
Rigel Pharmaceuticals USD 214.93M 39.53M Sep/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Veracyte USD 449.22M 34.54M Sep/2025